Gemcitabine + Nab-paclitaxel
Treatment for Pancreatic Cancer
Typical Dosage: Gemcitabine 1000 mg/m2, Nab-paclitaxel 125 mg/m2, on Days 1, 8, 15 of a 28-day cycle
Effectiveness
75%
Safety Score
25%
Clinical Trials
396
Participants
2.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Gemcitabine 1000 mg/m2, Nab-paclitaxel 125 mg/m2, on Days 1, 8, 15 of a 28-day cycle
Time to Effect
1-2 months
Treatment Duration
6-12 months, until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$15,000
Side Effect Mgmt:$25,000
Total Annual:$190,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$270,000/QALY
QALYs Gained
0.16
Outcome-Based Costs
Cost per Responder
$826,087
Comparison vs Gemcitabine
Cost Difference
+$120,000/year
More expensive
QALY Difference
+0.16 QALYs
Better outcomes
Dominance
No dominance
Gemcitabine + Nab-paclitaxel Outcomes
for Pancreatic Cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+23%
Common Side Effects
Neutropenia (Grade 3/4)
+38%
Fatigue (Grade 3/4)
+18%
Peripheral neuropathy (Grade 3/4)
+17%
Anemia (Grade 3/4)
+13%
Sources:
Active Clinical Trials
2 active trials recruiting for Gemcitabine + Nab-paclitaxel in Pancreatic Cancer
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
NCT05841420RECRUITINGPHASE2
98 participants
INTERVENTIONAL
Aalborg, Denmark
Started: Jun 12, 2023
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
NCT05497778ACTIVE NOT RECRUITINGPHASE1
19 participants
INTERVENTIONAL
Houston, United States
Started: Oct 21, 2022
Completed Clinical Trials
12 completed trials for Gemcitabine + Nab-paclitaxel in Pancreatic Cancer
Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer
NCT03807999COMPLETEDPHASE2
125 participants
INTERVENTIONAL
Started: Feb 19, 2015
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02993731COMPLETEDPHASE3
1.13K participants
INTERVENTIONAL
Birmingham, United States +266 more
Started: Dec 1, 2016
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
NCT02017015COMPLETEDPHASE2
83 participants
INTERVENTIONAL
Beijing, China +14 more
Started: Dec 24, 2013
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
NCT01715142COMPLETEDEARLY_PHASE1
23 participants
INTERVENTIONAL
Edegem, Belgium +1 more
Started: Mar 21, 2013
Treatment of Pancreatic Cancer With Abraxane
NCT02555813COMPLETED
317 participants
OBSERVATIONAL
Eisenstadt, Austria +18 more
Started: May 8, 2015
Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma
NCT02391662COMPLETEDPHASE2
80 participants
INTERVENTIONAL
Granollers, Spain +20 more
Started: Jun 23, 2015
A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer
NCT02272738COMPLETEDPHASE1
54 participants
INTERVENTIONAL
Osaka, Japan
Started: Aug 1, 2013
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
NCT01161186COMPLETEDPHASE1
15 participants
INTERVENTIONAL
San Francisco, United States +1 more
Started: Jul 1, 2010
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
NCT01298011COMPLETEDPHASE2
25 participants
INTERVENTIONAL
Scottsdale, United States +3 more
Started: May 1, 2011
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
NCT02707159COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Stavanger, Norway
Started: Nov 1, 2014
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
NCT02318095COMPLETEDNA
40 participants
INTERVENTIONAL
Durham, United States
Started: Feb 17, 2015
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
NCT02905578COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Iowa City, United States
Started: Nov 28, 2018
Showing 20 of 411 total trials